Single-Agent Subcutaneous Blinatumomab for Advanced B-Cell Acute Lymphoblastic Leukemia: Long-Term Follow-up from a Phase 1b Dose Expansion Cohort
Elias Jabbour(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Vaibhav Agrawal(City Of Hope National Medical Center), Gerhard Zugmaier(Amgen (Germany)), J. Rifón(Clinica Universidad de Navarra), Vladan Vučinić(University Hospital Leipzig), Boris Böll(University Hospital Cologne), Pilar Martínez‐Sánchez(Hospital Universitario 12 De Octubre), Paul Gordon(Amgen (United States)), Anita W. Rijneveld(Erasmus MC Cancer Institute), Maher Abdul‐Hay(NYU Langone’s Laura and Isaac Perlmutter Cancer Center), Ryan D. Cassaday(University of Washington), Thomas Cluzeau(Centre Hospitalier Universitaire de Nice), Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Françoise Huguet(Centre Hospitalier Universitaire de Toulouse)
Cited by 3
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
|Blood Cancer Journal|2017|1.3k